



Gabriel Mannis

Associate Professor of Medicine (Hematology)
Medicine - Hematology

CLINICAL OFFICE (PRIMARY)

- **Division of Hematology**

875 Blake Wilbur Dr
Stanford, CA 94305

Tel (650) 498-6000 Fax (650) 724-5203

Bio

BIO

Dr. Gabriel Mannis is Associate Professor of Medicine in the Division of Hematology at Stanford University School of Medicine, and Medical Director of Stanford's Inpatient Leukemia Service. He specializes in the treatment of acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS), and other hematologic malignancies. As a clinical scientist, Dr. Mannis divides his time between caring for patients, teaching trainees, and researching novel therapies for AML and MDS. Dr. Mannis has co-authored numerous publications on topics including AML, hematopoietic cell transplantation, and advanced care planning for patients with hematologic malignancies. Currently, Dr. Mannis serves on the National Comprehensive Cancer Network AML panel, helping to write evidence-based guidelines for how AML is best treated. He oversees the AML clinical trial portfolio at Stanford, with multiple clinical trials of novel drugs actively enrolling for both newly diagnosed and relapsed or refractory AML.

CLINICAL FOCUS

- Hematology
- Leukemia

ACADEMIC APPOINTMENTS

- Associate Professor - University Medical Line, Medicine - Hematology
- Member, Stanford Cancer Institute

ADMINISTRATIVE APPOINTMENTS

- Medical Director, Stanford Hospital Inpatient Hematology Service, (2021- present)
- Panel Member, Acute Leukemia Working Group, Southwest Oncology Group (SWOG), (2019- present)
- Panel Member, Acute Myeloid Leukemia Guidelines Committee, National Comprehensive Cancer Network, (2019- present)
- Member, Stanford Cancer Institute, (2019- present)

PROFESSIONAL EDUCATION

- Board Certification: Hematology, American Board of Internal Medicine (2015)
- Residency: UCSF Dept of Internal Medicine (2011) CA

- Fellowship: UCSF Hematology and Medical Oncology Fellowship (2014) CA
- Medical Education: University of California Davis School of Medicine (2008) CA

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

My research focuses on the development of more effective, less toxic therapies for patients with AML and other high-risk hematologic malignancies. We study biologic correlates that predict response to therapy as well as factors/interventions that improve quality-of-life for patients struggling with blood-borne cancers.

CLINICAL TRIALS

- (QUANTUM-WILD) (QUIZARTINIB OR PLACEBO PLUS CHEMOTHERAPY IN NEWLY DIAGNOSED PATIENTS WITH FLT3-ITD N, Recruiting
- A Long-term Extension Study of PCI-32765 (Ibrutinib), Recruiting
- Phase I/Ib Orally Available CLK Inhibitor BH-30236 in Relapsed / Refractory AML or Higher-Risk MDS, Recruiting
- Phase I/II HM43239 in Relapsed or Refractory Acute Myeloid Leukemia (AML), Recruiting
- Tagraxofusp and Low-Intensity Chemotherapy of CD123-Positive Relapsed or Refractory AML, Recruiting
- Feasibility of Telehealth-Based Palliative Care Intervention & Digital Symptom Monitoring in AML, Not Recruiting
- Ibrutinib vs Chlorambucil Extension Study (PCYC-1115-CA) in CLL or SLL, Not Recruiting
- Phase 1 CC-95251 +/- Antineoplastic Agents in Acute Myeloid Leukemia & Myelodysplastic Syndromes, Not Recruiting
- Phase 1b Magrolimab Monotherapy or Magrolimab in Combo w/ Azacitidine in Hematological Malignancies, Not Recruiting
- Phase I CPX-351 + Various Targeted Agents in Previously Untreated Acute Myeloid Leukemia, Not Recruiting
- Phase I IO-202 in Relapsed/Refractory AML w/ Monocytic Differentiation & in Relapsed/Refractory CMML, Not Recruiting
- Phase I/II IMGN632 MonoTx IV in CD123-Positive AML & Other CD123-Positive Hematologic Malignancies, Not Recruiting
- Phase I/II SNDX-5613 in Relapsed/Refractory Leukemias, Not Recruiting
- Phase II Comparing Venetoclax & Azacitidine to Induction ChemoTx in Newly Diagnosed Fit Adults w/ AML, Not Recruiting
- Phase II Magrolimab Combinations in Myeloid Malignancies, Not Recruiting
- Phase III Daunorubicin, Cytarabine, and Midostaurin or Placebo for Newly Diagnosed FLT3 Mutated AML, Not Recruiting
- Phase III Uproleselan + Chemotherapy vs Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia, Not Recruiting
- Study of Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination with Venetoclax in AML, Not Recruiting
- Phase tbd Specialty Compared to Oncology Delivered Palliative Care in Acute Myeloid Leukemia - SCOPE, Not Specified

Publications

PUBLICATIONS

- **Oncogenic SF3B1 mutations alter the splicing of mRNA noncoding regions to induce a novel therapeutic vulnerability.** *Blood*
Sekrecki, M., Sekrecka, A., Lattupally, R. R., Le, K., Jin, X., Mozes, C., Dwyer, B. G., Zhuang, Z., Romero, B. A., Pineda, J. M., Cao, X., Nguyen, L., Chen, et al
2026
- **Tuscany Study demonstrates safety and efficacy of tuspetinib plus standard of care venetoclax and azacitidine in patients with newly diagnosed AML ineligible for induction chemotherapy**
Mannis, G., Podoltsev, N., Jeyakumar, D., Watts, J., Vachhani, P., Jonas, B., Borate, U., Tam, E., Erba, H., Shi, Y., Haney, D., Rice, W., Bejar, et al
ELSEVIER.2025: 1645-1646
- **A phase 1/1b open-label, dose escalation, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-leukemic activity of the orally available clk inhibitor, BH-30236, in adults with R/R AML or HR-MDS**

Stein, E., Mims, A., Xie, Z., Mannis, G., Watts, J., Ravandi, F., Schiller, G., Ball, B., Liu, H., Altman, J., Wang, E., Cui, J., Zhou, et al
 ELSEVIER.2025: 1655-1656

- **Revumenib for patients with relapsed or refractory (R/R) KMT2Ar acute leukemia: Outcomes by leukemia type in the phase 2 AUGMENT-101 study**
 Aldoss, I., Issa, G., Blachly, J., Thirman, M., Mannis, G., Arellano, M., DiPersio, J., Traer, E., Zwaan, C., Shukla, N., Cuglievan, B., Grove, C., Greenwood, et al
 ELSEVIER.2025: 1001-1002
- **Patients with TP53-mutated AML/MDS without complex or monosomal karyotype can achieve durable survival benefits with allogeneic HCT**
 Jeyakumar, N., Torres, N., Godbole, S., Yamamoto, F., Zhang, B., Arai, S., Bharadwaj, S., Dahiya, S., Elmariah, H., Frank, M., Hosoya, H., Johnston, L., Meyer, et al
 ELSEVIER.2025: 2525-2526
- **Tagraxofusp and low-intensity chemotherapy for the treatment of CD123-positive relapsed or refractory Acute Myeloid Leukemia**
 Cho, W., Dutta, R., Cobarrubias, K., Inlow, E., Adre, N., Olson, N., Cunanan, K., Charu, V., Ediriwickrema, A., Zhang, T., Mannis, G.
 ELSEVIER.2025: 8256
- **Racial and ethnic disparities in u.S. chronic lymphocytic leukemia clinical trial enrollment: A participation-to-prevalence analysis**
 Bhaskar, A., Oh, A., Shomali, W., Mannis, G., Liedtke, M., Gotlib, J., Shanafelt, T., Fakhri, B.
 ELSEVIER.2025: 6308
- **Revumenib for patients with relapsed or refractory (R/R) Nucleophosmin 1-Mutated (NPM1m) Acute Myeloid Leukemia (AML): Outcomes by prior treatment in the phase 2 AUGMENT-101 study**
 Arellano, M., Thirman, M., DiPersio, J., Heiblig, M., Stein, E., Schuh, A., Zucenka, A., De Botton, S., Grove, C., Mannis, G., Papayannidis, C., Perl, A., Issa, et al
 ELSEVIER.2025: 3418-3419
- **Results from paradigm - a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed t adults with acute myeloid leukemia**
 Fathi, A., Perl, A., Fell, G., Jonas, B., Ragon, B., Mims, A., Borate, U., Mannis, G., Quillen, K., Stahl, M., Koller, P., Artz, A., Al Malki, et al
 ELSEVIER.2025: 6-7
- **Novel therapeutics for SF3B1 mutant cancers which exploit the missplicing of DCAF16**
 Sekrecki, M., Sekrecka, A., Lattupally, R., Le, K., Cao, X., Chen, V., Zhuang, Z., Dwyer, B., Zhou, C., Tiwari, C., Gabel, A., Kim, W., Stanley, et al
 ELSEVIER.2025: 1474-1475
- **A phase 1 study of IO-202, an anti-LILRB4 antibody, in chronic myelomonocytic leukemia and acute myeloid leukemia. *Blood neoplasia***
 Aribi, A., Mannis, G. N., Madanat, Y. F., Jonas, B. A., Dunavin, N., Roboz, G. J., Jeyakumar, D., Garcia-Manero, G., Liu, H., Carraway, H. E., Saultz, J. N., Blum, W., Schiller, et al
 2025; 2 (4): 100126
- **V-FAST: a phase 1b master trial to investigate CPX-351 combined with targeted agents in adults with newly diagnosed AML. *Blood neoplasia***
 Pullarkat, V. A., Levis, M., McCloskey, J., Mannis, G. N., Strickland, S. A., Fathi, A. T., Lin, T. L., Bhatt, V. R., Vanniyasingam, T., Chakravarthy, D., Lutska, Y., Faderl, S., Cheung, et al
 2025; 2 (4): 100123
- **Optimizing capillary leak syndrome prevention and management in patients receiving tagraxofusp for blastic plasmacytoid dendritic cell neoplasia. *Leukemia & lymphoma***
 Lane, A. A., Papayannidis, C., Angelucci, E., McCloskey, J., Schiller, G. J., de la Fuente Burguera, A., Montesinos, P., Nagarwala, Y., Herling, M., Mannis, G., Pemmaraju, N.
 2025: 1-9
- **Updated Results and Longer Follow-Up From the AUGMENT-101 Phase 2 Study of Revumenib in All Patients With Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia (AL)**
 Aldoss, I., Issa, G. C., Blachly, J. S., Thirman, M. J., Mannis, G. N., Arellano, M. L., Dipersio, J. F., Traer, E., Zwaan, C., Shukla, N., Cuglievan, B., Grove, C. S., Greenwood, et al
 CIG MEDIA GROUP, LP.2025

- **Patients With Relapsed or Refractory (R/R) Nucleophosmin 1-Mutated (NPM1m) Acute Myeloid Leukemia (AML): Updated Results From the Revumenib Phase 2 AUGMENT-101 Study**
Arellano, M. L., Thirman, M. J., DiPersio, J. F., Heiblig, M., Stein, E. M., Schuh, A. C., Zuc, A., De Botton, S., Grove, C. S., Mannis, G. N., Papayannidis, C., Perl, A. E., Issa, et al
CIG MEDIA GROUP.LP.2025: S400
- **Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Acute Myeloid Leukaemia. *EJHaem***
Mannis, G. N., Abboud, C. N., Daver, N. G., Murthy, G. S., Wang, E. S., Bradley, T. J., Yagmour, G., Vachhani, P., Balasubramanian, S. K., Chua, C. C., Fong, C. Y., Asch, A. S., Dong, et al
2025; 6 (3): e70051
- **Tagraxofusp and low-intensity chemotherapy for the treatment of CD123-positive relapsed or refractory acute myeloid leukemia.**
Cho, W., Dutta, R., de Santiago, V., Cobarrubias, K., Choi, J., Inlow, E., Shaw, B., Cunanan, K., Charu, V., Ediriwickrema, A., Zhang, T., Mannis, G. N.
LIPPINCOTT WILLIAMS & WILKINS.2025: TPS6582
- **An all-oral regimen of decitabine-cedazuridine (DEC-C) plus venetoclax (VEN) in patients (pts) with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy: Results from a phase 2 cohort of 101 pts**
Zeidan, A., Griffiths, E. A., Dinardo, C., Mannis, G. N., Montesinos, P., Arnan, M., Savona, M. R., Odenike, O., McCloskey, J. K., Amin, H. V., Fathi, A., Bernal Del Castillo, T., Rodriguez-Macias, et al
LIPPINCOTT WILLIAMS & WILKINS.2025
- **Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study. *Blood***
Arellano, M. L., Thirman, M. J., DiPersio, J. F., Heiblig, M., Stein, E. M., Schuh, A. C., Zucenka, A., De Botton, S., Grove, C. S., Mannis, G. N., Papayannidis, C., Perl, A. E., Issa, et al
2025
- **The improved prognosis of FLT3-internal tandem duplication but not tyrosine kinase domain mutations in acute myeloid leukemia in the era of targeted therapy: a realworld study using large-scale electronic health record data. *Haematologica***
Schwede, M., Rodriguez, G., Kennedy, V. E., Henry, S., Wood, D., Mannis, G. N., Majeti, R., Chen, J. H., Bendavid, E., Zhang, T. Y.
2025
- **Prognostic Significance of Low Copy Number<i> FLT3</i> and<i> NPM1</i> mrd As Detected By Ultra-Sensitive Next Generation Sequencing**
Shannon, M. L., Zhang, T. Y., Muffy, L., Mannis, G. N.
ELSEVIER.2024: 4330-4331
- **Phase 1 Safety and Efficacy of Tuspentinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspentinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML**
Daver, N., Lee, K., Choi, Y., Montesinos, P., Jonas, B. A., Arellano, M. L., Borate, U., Watts, J. M., Koller, P. B., Jung, C., Sohn, S., Fathi, A. T., Vachhani, et al
ELSEVIER.2024: 4255-4258
- **Prognostic Significance of CD123 Expression in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents**
Tiu, B. C., Su, C. J., St Martin, E. C., Oak, J. S., Zhang, T. Y., Mannis, G. N.
ELSEVIER.2024: 6104-6105
- **A Phase 1/1b Open-Label, Dose Escalation, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Leukemic Activity of the Orally Available CDC-like Kinase Inhibitor, BH-30236, in Adults with R/R AML or HR-MDS**
Stein, E. M., Boussi, L., Mims, A., Watts, J. M., Mannis, G. N., Liu, H., Sallman, D., Ravandi, F., Schiller, G. J., Wang, E. S., Ball, B. J., Cui, J., Zhou, et al
ELSEVIER.2024: 5999-6000
- **10-202, a Novel Anti-LILRB4 Antibody, with Azacitidine for Hypomethylating Agent-Naive Chronic Myelomonocytic Leukemia: Phase 1b Expansion Cohort Results**
Mannis, G. N., Aribi, A., Dunavin, N., Carraway, H. E., Saultz, J. N., Roboz, G. J., Jonas, B. A., Madanat, Y. F., Garcia-Manero, G., Jeyakumar, D., Pollyea, D. A., Odenike, O., Blum, et al
ELSEVIER.2024: 1009-1010
- **Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R)<i> KMT2Ar</i> Acute Leukemia**

Aldoss, I., Issa, G. C., Blachly, J. S., Thirman, M. J., Mannis, G. N., Arellano, M. L., Dipersio, J. F., Traer, E., Zwaan, C., Shukla, N., Cuglievan, B., Grove, C. S., Greenwood, et al
ELSEVIER.2024: 211-214

- **Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 Trial**
Deangelo, D. J., Schuh, A. C., Jonas, B. A., Becker, P. S., Advani, A. S., Uy, G. L., Krawczyk, J., Erba, H. P., Mannis, G. N., Fong, C., Kuchenbauer, F., Percival, M. M., Liesveld, et al
ELSEVIER.2024: 733-735
- **Characterization and Clinical Outcome of Philadelphia Chromosome-Positive AML in Thrombocytopenia-Absent Radius Syndrome. *JCO precision oncology***
Villar-Prados, A., Odabas, A., Menke, J. R., Kingham, K., Mannis, G. N.
2024; 8: e2400411
- **Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101). *Journal of clinical oncology : official journal of the American Society of Clinical Oncology***
Issa, G. C., Aldoss, I., Thirman, M. J., DiPersio, J., Arellano, M., Blachly, J. S., Mannis, G. N., Perl, A., Dickens, D. S., McMahon, C. M., Traer, E., Zwaan, C. M., Grove, et al
2024: JCO2400826
- **p53 immunohistochemistry as an ancillary tool for rapid assessment of residual disease in TP53-mutated acute myeloid leukemia and myelodysplastic syndromes. *American journal of clinical pathology***
Brar, N., Lawrence, L., Fung, E., Zehnder, J. L., Greenberg, P. L., Mannis, G. N., Zhang, T. Y., Gratzinger, D., Oak, J., Silva, O., Kurzer, J., Tan, B., Menke, et al
2024
- **CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123. *Leukemia research***
Hu, X., Ediriwickrema, A., Saleem, A., Tan, B., Pemmaraju, N., Mannis, G. N.
2024; 139: 107479
- **Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations. *Leukemia & lymphoma***
Pemmaraju, N., Madanat, Y. F., Rizzieri, D., Fazal, S., Rampal, R., Mannis, G., Wang, E. S., Foran, J., Lane, A. A.
2024: 1-12
- **Analysis of Treatment Patterns and Outcomes in Patients Ages 60-74 in the PostVenetoclax Era**
St Martin, E. C., Schwede, M., Fakhri, B., Gotlib, J., Liedtke, M., Shomali, W., Zhang, T. Y., Mannis, G.
AMER SOC HEMATOLOGY.2023
- **A Phase 2 Study with Volasertib for Ven-HMA Relapsed/Refractory Acute Myeloid Leukemia Patients Guided By a Predictive Precision Medicine Platform**
Wagner, J., Lacher, M. D., Gu, C. J., Leonardi, C., Mannis, G.
AMER SOC HEMATOLOGY.2023
- **Acute Myeloid Leukemia with Inv(3) or t(3;3): A Clinical and Cytogenetic Characterization of 40 Patients**
Moscvin, M., Schwede, M., Mannis, G., Zhang, T. Y.
AMER SOC HEMATOLOGY.2023
- **Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemias: Efficacy and Safety Results from the Augment-101 Phase 1/2 Study**
Aldoss, I., Issa, G. C., Thirman, M. J., DiPersio, J., Arellano, M., Blachly, J. S., Mannis, G., Perl, A., Dickens, D., McMahon, C. M., Traer, E., Zwaan, C., Grove, et al
AMER SOC HEMATOLOGY.2023
- **Development of Circulating Tumor DNA (ctDNA) for Molecular Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML)**
Gunaratne, R., Zhou, C., Tai, J. W., Schwede, M., Tanaka, K., Alkaitis, M., Yin, R., Sworder, B. J., Mannis, G., Majeti, R., Khodadoust, M. S., Kurtz, D. M., Zhang, et al
AMER SOC HEMATOLOGY.2023
- **Cladribine and Low-Dose Cytarabine-Based Salvage Therapy for Relapsed/Refractory AML in a Predominantly Venetoclax-Exposed Cohort**

- Cheung, E., Schumann, C., Zhang, T. Y., Fakhri, B., Gotlib, J., Liedtke, M., Shomali, W., Mannis, G.
AMER SOC HEMATOLOGY.2023
- **Immunosuppression in Isocitrate Dehydrogenase Mutated Acute Myeloid Leukemia**
Tai, J. W., Li, G., Tanaka, K., Gopakumar, J., Zhou, C., Linde, M., Villar-Prados, A., Rangavajhula, A. S., Trotman-Grant, A. C., Landberg, N., Fan, A. C., Mannis, G., Zhang, et al
AMER SOC HEMATOLOGY.2023
 - **Phase 1b/2 Trial of Enasidenib in Lower-Risk MDS and Nonproliferative CMML without Isocitrate Dehydrogenase Type 2 Mutations**
Kuo, E., Santiago, V., Tanaka, K., Puram, V., Zhou, C., Tai, J. W., Mannis, G., Majeti, R., Zhang, T. Y.
AMER SOC HEMATOLOGY.2023
 - **The Shifting Prognosis of FLT3 Mutations in Acute Myeloid Leukemia in the Era of Targeted Therapy: A Real-World Study Using Large-Scale Electronic Health Record Data**
Schwede, M., Rodriguez, G., Henry, S., Wood, D., Mannis, G., Majeti, R., Chen, J., Bendavid, E., Zhang, T. Y.
AMER SOC HEMATOLOGY.2023
 - **Harnessing Artificial Intelligence for Risk Stratification in Acute Myeloid Leukemia (AML): Evaluating the Utility of Longitudinal Electronic Health Record (EHR) Data Via Graph Neural Networks**
Sinha, R., Schwede, M., Ben Viggiano, Kuo, D., Henry, S., Wood, D., Mannis, G., Majeti, R., Chen, J., Zhang, T. Y.
AMER SOC HEMATOLOGY.2023
 - **Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study**
Aldoss, I., Issa, G. C., Thirman, M., DiPersio, J., Arellano, M., Blachly, J. S., Mannis, G. N., Perl, A., Dickens, D. S., McMahon, C. M., Traer, E., Zwaan, C., Grove, et al
AMER SOC HEMATOLOGY.2023
 - **Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia. *Leukemia & lymphoma***
Gaut, D., Oliyai, C., Boiarsky, J., Zhang, S., Salhotra, A., Azenkot, T., Kennedy, V. E., Khanna, V., Olmedo Gutierrez, K., Shukla, N., Moskoff, B., Park, G., Afkhami, et al
2023: 1-9
 - **Tolerability and Efficacy of the Anticlusteral Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology***
Daver, N. G., Vyas, P., Kambhampati, S., Al Malki, M. M., Larson, R. A., Asch, A. S., Mannis, G., Chai-Ho, W., Tanaka, T. N., Bradley, T. J., Jeyakumar, D., Wang, E. S., Sweet, et al
2023: JCO2202604
 - **Association of geriatric measures and global frailty with cognitive decline after allogeneic hematopoietic cell transplantation in older adults. *Journal of geriatric oncology***
Huang, L. W., Shi, Y., Andreadis, C., Logan, A. C., Mannis, G. N., Smith, C. C., Gaensler, K. M., Martin, T. G., Damon, L. E., Boscardin, W. J., Steinman, M. A., Olin, R. L.
2023; 14 (8): 101623
 - **Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts. *The Lancet. Haematology***
Shallis, R. M., Daver, N., Altman, J. K., Komrokji, R. S., Pollyea, D. A., Badar, T., Bewersdorf, J. P., Bhatt, V. R., de Botton, S., de la Fuente Burguera, A., Carraway, H. E., Desai, P., Dillon, et al
2023
 - **Outcomes with molecularly targeted agents as salvage therapy following frontline venetoclax + hypomethylating agent in adults with acute myeloid leukemia: A multicenter retrospective analysis. *Leukemia research***
Khanna, V., Azenkot, T., Liu, S. Q., Gilbert, J., Cheung, E., Lau, K., Pollyea, D. A., Traer, E., Jonas, B. A., Zhang, T. Y., Mannis, G. N.
2023; 131: 107331
 - **Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology. *Journal of the National Comprehensive Cancer Network : JNCCN***
Pollyea, D. A., Altman, J. K., Assi, R., Bixby, D., Fathi, A. T., Foran, J. M., Gojo, I., Hall, A. C., Jonas, B. A., Kishtagari, A., Lancet, J., Maness, L., Mangan, et al
2023; 21 (5): 503-513

- **Older Adults With Newly Diagnosed AML: Hot Topics for the Practicing Clinician.** *American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting*
Lai, C., Bhansali, R. S., Kuo, E. J., Mannis, G., Lin, R. J.
2023; 43: e390018
- **Older Adults With Newly Diagnosed AML: Hot Topics for the Practicing Clinician.** *American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting*
Lai, C., Bhansali, R. S., Kuo, E. J., Mannis, G., Lin, R. J.
2023; 43: e390018
- **The Goldilocks Dilemma in AML: Too Young and Fit, but Not Young and Fit Enough.** *Clinical lymphoma, myeloma & leukemia*
St Martin, E. C., Zhang, T. Y., Mannis, G. N.
2023
- **Value of embedded palliative care: outpatient palliative care and healthcare utilization for hematologic malignancies.** *Blood advances*
Tsang, M., Bischoff, K. E., Schoenbeck, K. L., Berry, K., O'Riordan, D., Fakhri, B., Wong, S. W., Shah, N., Olin, R. L., Andreadis, C., Vieaux, J., Cohen, E., Shepard Lopez, et al
2023
- **North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: Position on Standards of Care and Areas of Need.** *Blood*
Pemmaraju, N., Kantarjian, H. M., Sweet, K. L., Wang, E. S., Senapati, J., Wilson, N. R., Konopleva, M. Y., Frankel, A. E., Gupta, V., Mesa, R. A., Ulrickson, M. L., Gorak, E., Bhatia, et al
2022
- **Outcomes with Molecularly Targeted Agents As Salvage Therapy Following Frontline HMA/Venetoclax in Adults with Acute Myeloid Leukemia: A Multi-Center Retrospective Analysis**
Khanna, V., Azenkot, T., Liu, S., Gilbert, J., Cheung, E., Lau, K., Pollyea, D. A., Traer, E., Jonas, B. A., Zhang, T. Y., Mannis, G. N.
AMER SOC HEMATOLOGY.2022: 3294-3296
- **V-FAST Master Trial: Subgroup Analysis of Outcomes with CPX-351 Plus Midostaurin in Adults with Newly Diagnosed Acute Myeloid Leukemia By FLT3 Mutation Type**
McCloskey, J., Pullarkat, V. A., Mannis, G. N., Lin, T. L., Strickland, S. A., Fathi, A. T., Faderl, S., Chakravarthy, D., Lutska, Y., Chandrasekaran, V., Cheung, R. S., Levis, M. J.
AMER SOC HEMATOLOGY.2022: 3312-3314
- **Measurable Residual Disease Conversion Rate with Consolidation Chemotherapy in Acute Myeloid Leukemia**
Gaut, D., Oliari, C., Boiarsky, J., Zhang, S., Azenkot, T., Kennedy, V. E., Khanna, V., Gutierrez, K., Shukla, N. D., Moskoff, B., Patel, A., Jeyakumar, D., Mannis, et al
AMER SOC HEMATOLOGY.2022: 3374-3376
- **AML-464 Tolerability and Efficacy of the First-In-Class Anti-CD47 Antibody Magrolimab Combined With Azacitidine in Frontline Patients With TP53-Mutated Acute Myeloid Leukemia (AML): Phase 1b Results.** *Clinical lymphoma, myeloma & leukemia*
Daver, N., Vyas, P., Kambhampati, S., Malki, M. A., Larson, R., Asch, A., Mannis, G., Chai-Ho, W., Tanaka, T., Bradley, T., Jeyakumar, D., Wang, E., Xing, et al
2022; 22 Suppl 2: S253-S254
- **Tolerability and Efficacy of the First-In-Class Anti-CD47 Antibody Magrolimab Combined With Azacitidine in Frontline Patients With TP53-Mutated Acute Myeloid Leukemia (AML): Phase 1b Results**
Daver, N., Vyas, P., Kambhampati, S., Al Malki, M., Larson, R., Asch, A., Mannis, G., Chai-Ho, W., Tanaka, T., Bradley, T., Jeyakumar, D., Wang, E., Xing, et al
CIG MEDIA GROUP, LP.2022: S253-S254
- **Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results.**
Daver, N., Vyas, P., Kambhampati, S., Al Malki, M. M., Larson, R. A., Asch, A., Mannis, G. N., Chai-Ho, W., Tanaka, T. N., Bradley, T. J., Jeyakumar, D., Wang, E. S., Xing, et al
LIPPINCOTT WILLIAMS & WILKINS.2022
- **V-FAST master trial: Preliminary results of treatment with CPX-351 plus midostaurin in adults with newly diagnosed FLT3-mutated acute myeloid leukemia.**
McCloskey, J. K., Pullarkat, V. A., Mannis, G. N., Lin, T. L., Strickland, S., Fathi, A., Erba, H., Faderl, S., Chakravarthy, D., Lutska, Y., Chandrasekaran, V., Cheung, R., Levis, et al

LIPPINCOTT WILLIAMS & WILKINS.2022

- **Embedded outpatient palliative care for hematologic malignancies: Referral patterns and health care utilization.**
Tsang, M., Bischoff, K. E., Schoenbeck, K. L., Berry, K., O'Riordan, D., Fakhri, B., Wong, S., Shah, N., Cohen, E., Lopez, N., Mannis, G. N., Rabow, M. W.
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Patterns and predictors of functional decline after alloHCT in older adults.** *Transplantation and cellular therapy*
Huang, L. W., Sheng, Y., Andreadis, C., Logan, A. C., Mannis, G. N., Smith, C. C., Gaensler, K. M., Martin, T. G., Damon, L. E., Huang, C. Y., Olin, R. L.
2022
- **Outcomes of Allogeneic Transplantation after Hypomethylating Agents with Venetoclax in Acute Myeloid Leukemia.** *American journal of hematology*
Kennedy, V. E., Hui, G., Azenkot, T., Gaut, D., Wieduwilt, M. J., Oliai, C., Jonas, B. A., Mittal, V., Logan, A. C., Muffly, L. S., Mannis, G. N.
2022
- **Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent.** *British journal of haematology*
On, S., Rath, C. G., Lan, M., Wu, B., Lau, K. M., Cheung, E., Alegria, W., Young, R., Tan, M., Kim, C., Phun, J., Patel, N., Mannis, et al
2022
- **Gilteritinib Clinical Activity in Relapsed/Refractory FLT3 Mutated AML Previously Treated with FLT3 inhibitors.** *American journal of hematology*
Numan, Y., Abdel Rahman, Z., Grenet, J., Boisclair, S., Bewersdorf, J. P., Collins, C., Barth, D., Fraga, M., Bixby, D. L., Zeidan, A. M., Yilmaz, M., Desai, P., Mannis, et al
2022
- **Preliminary Results By Age Group of Treatment with CPX-351 Plus Venetoclax in Adults with Newly Diagnosed AML: Subgroup Analysis of the V-FAST Phase 1b Master Trial**
Pullarkat, V. A., Levis, M., Mannis, G. N., Strickland, S. A., Lin, T. L., Faderl, S., Chakravarthy, D., Chandrasekaran, V., Cheung, R. S., Erba, H. P.
AMER SOC HEMATOLOGY.2021
- **The First-in-Class Anti-CD47 Antibody Magrolimab in Combination with Azacitidine Is Well Tolerated and Effective in AML Patients: Phase 1b Results**
Sallman, D., Asch, A., Kambhampati, S., Al Malki, M., Zeidner, J., Donnellan, W., Lee, D., Vyas, P., Jeyakumar, D., Mannis, G., Tanaka, T., Chai-Ho, W., Larson, et al
CIG MEDIA GROUP, LP.2021: S290
- **Measurable Residual Disease Status and FLT3 Inhibitor Therapy in Patients with FLT3-ITD-Mutated AML Following Allogeneic Hematopoietic Cell Transplantation**
Liang, E. C., Chen, C., Lu, R., Mannis, G. N., Muffly, L.
CIG MEDIA GROUP, LP.2021: S278-S279
- **Feasibility Study Integrating Electronic Patient-Reported Outcomes (PROs) and Palliative Care for High-Risk Acute Myeloid Leukemia (AML) Patients**
Tan, I., Choi, J., Cunanan, K., Fronk, J., Zhang, T., Mannis, G. N., Ramchandran, K.
CIG MEDIA GROUP, LP.2021: S279-S280
- **Preliminary results of V-FAST, a phase 1b master trial to investigate CPX-351 combined with targeted agents in newly diagnosed AML.**
Pullarkat, V., Levis, M. J., Mannis, G. N., Strickland, S., Lin, T. L., Faderl, S., Chakravarthy, D., Chandrasekaran, V., Cheung, R., Erba, H.
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Event free survival in adults with relapsed ALL who underwent front-line therapy with CALGB 10403.**
Raychaudhuri, S., Yurkiewicz, I., Mannis, G. N., Medeiros, B. C., Coutre, S. E., Muffly, L. S., Liedtke, M.
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Routine use of gemtuzumab ozogamicin in 7 + 3-based inductions for all 'non-adverse' risk AML.** *Leukemia & lymphoma*
Ladha, A. n., Hui, G. n., Cheung, E. n., Berube, C. n., Coutre, S. E., Gotlib, J. n., Liedtke, M. n., Zhang, T. Y., Muffly, L. n., Mannis, G. N.
2021: 1–6

- **Heterogeneous Definitions of Secondary Acute Myeloid Leukemia (AML) Yield Distinct Outcomes in Response to First-Line Treatment with Hypomethylating Agents (HMA) and Venetoclax (Ven)**
Tan, I., Schwede, M., Phan, P., Yin, R., Zhang, T. Y., Mannis, G. N.
2021
- **Inhibition of MET Signaling with Ficlaturuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis.** *Blood cancer discovery*
Wang, V. E., Blaser, B. W., Patel, R. K., Behbehani, G. K., Rao, A. A., Durbin-Johnson, B., Jiang, T., Logan, A. C., Settles, M., Mannis, G. N., Olin, R., Damon, L. E., Martin, et al
2021; 2 (5): 434-449
- **Measurable residual disease status and FLT3 inhibitor therapy in patients with FLT3-ITD mutated AML following allogeneic hematopoietic cell transplantation.** *Bone marrow transplantation*
Liang, E. C., Chen, C., Lu, R., Mannis, G. N., Muffy, L.
2021
- **Epstein-Barr virus-positive lymphoproliferative disorder manifesting as pulmonary disease in a patient with acute myeloid leukemia: a case report.** *Journal of medical case reports*
Dutta, R. n., Miao, S. Y., Phan, P. n., Fernandez-Pol, S. n., Shiraz, P. n., Ho, D. n., Mannis, G. N., Zhang, T. Y.
2021; 15 (1): 170
- **NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021.** *Journal of the National Comprehensive Cancer Network : JNCCN*
Pollyea, D. A., Bixby, D. n., Perl, A. n., Bhatt, V. R., Altman, J. K., Appelbaum, F. R., de Lima, M. n., Fathi, A. T., Foran, J. M., Gojo, I. n., Hall, A. C., Jacoby, M. n., Lancet, et al
2021; 19 (1): 16–27
- **Hypomethylating agents super-responders: challenging the dogma of long-term remission for acute myeloid leukemia.** *Annals of hematology*
Maakaron, J. E., Ozga, M. P., Mannis, G. N., Pulley, W., Foster, M. C., Zeidner, J. F., Mims, A. S.
2020
- **Hepatic veno-occlusive disease in allogeneic stem cell transplant recipients with prior exposure to gemtuzumab ozogamicin or inotuzumab ozogamicin.** *Leukemia & lymphoma*
Ladha, A. n., Mannis, G. n., Muffy, L. n.
2020: 1–7
- **Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience.** *Leukemia & lymphoma*
Azizi, A. n., Ediriwickrema, A. n., Dutta, R. n., Patel, S. A., Shomali, W. n., Medeiros, B. n., Iberri, D. n., Gotlib, J. n., Mannis, G. n., Greenberg, P. n., Majeti, R. n., Zhang, T. n.
2020: 1–8
- **Improved Outcomes of Octogenarians and Nonagenarians with Acute Myeloid Leukemia in the Era of Novel Therapies.** *American journal of hematology*
Jeng, M. Y., Dutta, R. n., Tan, I. T., Zhang, T. Y., Mannis, G. N.
2020
- **Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy.** *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*
Dholaria, B. n., Savani, B. N., Hamilton, B. K., Oran, B. n., Liu, H. D., Tallman, M. S., Ciurea, S. O., Holtzman, N. G., Li, G. L., Devine, S. M., Mannis, G. n., Grunwald, M. R., Appelbaum, et al
2020
- **Venetoclax monotherapy for cutaneous blastic plasmacytoid dendritic cell neoplasm.** *Annals of hematology*
Schwede, M. n., Tan, I. T., Atibalentja, D. F., Dickman, M. M., Rieger, K. E., Mannis, G. N.
2020
- **Serial comprehensive geriatric and quality of life assessments in adults age ≥ 50 years undergoing autologous hematopoietic cell transplantation.** *Journal of geriatric oncology*
Nawas, M. T., Sheng, Y. n., Huang, C. Y., Andreadis, C. n., Martin, T. G., Wolf, J. L., Ai, W. Z., Kaplan, L. D., Mannis, G. N., Logan, A. C., Damon, L. E., Olin, R. L.

2020

- **Maintenance Lenalidomide in Primary CNS Lymphoma.** *Annals of oncology : official journal of the European Society for Medical Oncology*
Rubenstein, J. L., Geng, H., Vu, K., Mannis, G., Formaker, P., Hwang, J., Munster, P. N., Damato, B.
2019
- **Low-dose lenalidomide maintenance after induction therapy in older patients with primary central nervous system lymphoma.** *British journal of haematology*
Vu, K., Mannis, G., Hwang, J., Geng, H., Rubenstein, J. L.
2019
- **Limitation in Patient-Reported Function Is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.** *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*
Nawas, M. T., Andreadis, C., Martin, T. G., Wolf, J. L., Ai, W. Z., Kaplan, L. D., Mannis, G. N., Logan, A. C., Damon, L. E., Huang, C., Olin, R. L.
2019
- **Allogeneic HSCT for adult-onset leukoencephalopathy with spheroids and pigmented glia.** *Brain : a journal of neurology*
Gelfand, J. M., Greenfield, A. L., Barkovich, M. n., Mendelsohn, B. A., Van Haren, K. n., Hess, C. P., Mannis, G. N.
2019
- **Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.** *Journal of the National Comprehensive Cancer Network : JNCCN*
Tallman, M. S., Wang, E. S., Altman, J. K., Appelbaum, F. R., Bhatt, V. R., Bixby, D. n., Coutre, S. E., De Lima, M. n., Fathi, A. T., Fiorella, M. n., Foran, J. M., Hall, A. C., Jacoby, et al
2019; 17 (6): 721–49
- **Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.** *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*
Huang, L. W., Sheng, Y. n., Andreadis, C. n., Logan, A. C., Mannis, G. N., Smith, C. C., Gaensler, K. M., Martin, T. G., Damon, L. E., Steinman, M. A., Huang, C. Y., Olin, R. L.
2019
- **Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.** *Blood*
Roboz, G. J., DiNardo, C. D., Stein, E. M., de Botton, S. n., Mims, A. S., Prince, G. T., Altman, J. K., Arellano, M. L., Donnellan, W. n., Erba, H. P., Mannis, G. N., Pollyea, D. A., Stein, et al
2019
- **Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML** *NEW ENGLAND JOURNAL OF MEDICINE*
DiNardo, C. D., Stein, E. M., de Botton, S., Roboz, G. J., Altman, J. K., Mims, A. S., Swords, R., Collins, R. H., Mannis, G. N., Pollyea, D. A., Donnellan, W., Fathi, A. T., Pigneux, et al
2018; 378 (25): 2386–98
- **Venetoclax in Combination with Decitabine for Relapsed T-Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplant** *CASE REPORTS IN HEMATOLOGY*
Rahmat, L. T., Nguyen, A., Abdulhaq, H., Prakash, S., Logan, A. C., Mannis, G. N.
2018: 6092646
- **Discussion on reply to Foley et al., 'Acute myeloid leukemia with t(14;21) involving RUNX1 and SYNE2: A novel favorable-risk translocation?'** *CANCER GENETICS*
Mannis, G. N.
2018; 220: 77–78
- **Acute myeloid leukemia with t(14;21) involving RUNX1 and SYNE2: A novel favorable-risk translocation?** *CANCER GENETICS*
Foley, N., Van Ziffle, J., Yu, J., Qi, Z., Grenert, J. P., Yeh, I., Bastian, B., Kogan, S., Mannis, G. N.
2017; 216: 74–78
- **Advance care planning and end-of-life care for patients with hematologic malignancies who die after hematopoietic cell transplant.** *Bone marrow transplantation*
Eckhart, E. E., Schoenbeck, K. L., Galligan, D., McNey, L. M., Hwang, J., Mannis, G. N.
2017; 52 (6): 929-931

- **Regression of methotrexate-resistant AIDS-related primary central nervous system lymphoma with lenalidomide plus combination anti-retroviral therapy** *LEUKEMIA & LYMPHOMA*
Gupta, N. K., Wang, C., Mannis, G. N., Yu, J. J., Rubenstein, J. L.
2017; 58 (11): 2748–51
- **Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Mule, M. P., Mannis, G. N., Wood, B. L., Radich, J. R., Hwang, J., Ramos, N. R., Andreadis, C., Damon, L., Logan, A. C., Martin, T. G., Hourigan, C. S.
2016; 22 (11): 1974–82
- **Paraproteinemic keratopathy as the presenting sign of hematologic malignancy** *AMERICAN JOURNAL OF HEMATOLOGY*
Mannis, T. E., Mannis, G. N., Waterhouse, E. G., Aldave, A. J., Rose-Nussbaumer, J.
2016; 91 (9): 961–62
- **Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Mannis, G. N., Martin, T. G., Damon, L. E., Andreadis, C., Olin, R. L., Kong, K. A., Faham, M., Hwang, J., Ai, W. Z., Gaensler, K. M. L., Sayre, P. H., Wolf, J. L., Logan, et al
2016; 22 (6): 1030–36
- **Inferior vena cava filter thrombosis** *CLINICAL CASE REPORTS*
Byrne, M., Mannis, G. N., Nair, J., Andreadis, C.
2016; 4 (2): 162–64
- **Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission** *LEUKEMIA & LYMPHOMA*
Mannis, G. N., Martin, T. G., Damon, L. E., Logan, A. C., Olin, R. L., Flanders, M. D., Ai, W. Z., Gaensler, K. M. L., Kaplan, L. D., Sayre, P. H., Smith, C. C., Wolf, J. L., Andreadis, et al
2016; 57 (7): 1560–66
- **Long-term survival in AIDS-related primary central nervous system lymphoma.** *Neuro-oncology*
Gupta, N. K., Nolan, A. n., Omuro, A. n., Reid, E. G., Wang, C. C., Mannis, G. n., Jaglal, M. n., Chavez, J. C., Rubinstein, P. G., Griffin, A. n., Abrams, D. I., Hwang, J. n., Kaplan, et al
2016
- **The Transfusion Tether: Bridging the Gap Between End-Stage Hematologic Malignancies and Optimal End-of-Life Care.** *American journal of hematology*
Mannis, G. N., McNey, L. M., Gupta, N. K., Gross, D. M.
2016
- **A Phase I Study of Targeted, Dose-Escalated Intravenous Busulfan in Combination With Etoposide as Myeloablative Therapy for Autologous Stem Cell Transplantation in Acute Myeloid Leukemia** *CLINICAL LYMPHOMA MYELOMA & LEUKEMIA*
Mannis, G. N., Andreadis, C., Logan, A. C., Damon, L. E., Benet, L. Z., Ai, W. Z., Gaensler, K. M. L., Kaplan, L. D., Koplowicz, Y. B., Linker, C. A., Olin, R. L., Sayre, P. H., Smith, et al
2015; 15 (6): 377–83
- **Ibrutinib rash in a patient with 17p del chronic lymphocytic leukemia.** *American journal of hematology*
Mannis, G., Wu, D., Dea, T., Mauro, T., Hsu, G.
2015; 90 (2): 179
- **Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis** *BONE MARROW TRANSPLANTATION*
Mannis, G. N., Logan, A. C., Leavitt, A. D., Yanada, M., Hwang, J., Olin, R. L., Damon, L. E., Andreadis, C., Ai, W. Z., Gaensler, K. M., Greene, C. C., Gupta, N. K., Kaplan, et al
2015; 50 (1): 40–44
- **How I treat CNS lymphomas** *BLOOD*
Rubenstein, J. L., Gupta, N. K., Mannis, G. N., LaMarre, A. K., Treseler, P.
2013; 122 (14): 2318–2330

- **Risk-Reducing Salpingo-oophorectomy and Ovarian Cancer Screening in 1077 Women After BRCA Testing** *JAMA INTERNAL MEDICINE*
Mannis, G. N., Fehniger, J. E., Creasman, J. S., Jacoby, V. L., Beattie, M. S.
2013; 173 (2): 96–103